Skip to search formSkip to main contentSkip to account menu

halobetasol propionate

Known as: 21-Chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate, 6 alpha-fluoroclobetasol 17-propionate, 6-fluoroclobetasol 17-propionate 
The propionate salt form of halobetasol, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictor activities. Halobetasol… 
National Institutes of Health

Related topics

Related topics

13 relations
Decreased Protein Synthesis [PE]Facial DermatosesFoot DermatosesGlucocorticoid Receptor Agonists [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities.
Background: Plaque psoriasis can occur in all body regions, with the trunk and extremities among the most commonly affected areas… 
2019
2019
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis
Recently, clinical data on 8 weeks’ once-daily treatment of localized moderate-to-severe psoriasis with a novel fixed combination… 
2019
2019
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy
BACKGROUND: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Topical… 
2018
2018
Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.
BACKGROUND Topical corticosteroids (TCS) are the mainstay of psoriasis treatment; long-term safety concerns limiting consecutive… 
2017
2017
Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque…
BACKGROUND: A novel lotion formulation of halobetasol propionate, 0.05% (HBP Lotion) with enhanced vehicle characteristics of a… 
2017
2017
Halobetasol Propionate Lotion, 0.05% Provides Superior Hydration Compared to Halobetasol Propionate Cream, 0.05% in a Double-Blinded Study of Occlusivity and Hydration.
BACKGROUND This study measured skin hydration and occlusivity of two test products [halobetasol propionate lotion, 0.05% (HBP… 
2016
2016
EVALUATION OF THE EFFICACY AND SAFETY OF 0.05% HALOBETASOL PROPIONATE OINTMENT AND 0.05% CLOBETASOL PROPIONATE OINTMENT IN CHRONIC, LOCALIZED PLAQUE PSORIASIS
Psoriasis is a common, chronic, inflammatory, multisystem disease involving the skin and joints. It accounts for 2.3% of the… 
2010
2010
Simultaneous Determination of Halobetasol and Salicylic Acid Related Substances by Reversed Phase High Performance Liquid Chromatographic Method
A simple fast, accurate, precise and cost effective reverse phase high performance liquid chromatographic method is developed for… 
2008
2008
Formulation and evaluation of novel combined halobetasol propionate and fusidic acid ointment
Present investigation is to developed Novel ointment formulation in combination of Halobetasol propionate and Fusidic acid for… 
1991
1991
Halobetasol propionate: a trihalogenated ultrapotent topical corticosteroid.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)